Our Vision
To commercialize revolutionary technologies in the niche of genomics, building our company as a world leader in personalized medicine.
Financing Sought:
Rs.50 Million ($300K)
Total Addressable Market (Pakistan)
Rs.7.5 Billion
Serviceable Obtainable Market (Pakistan)
Rs.750 Million
Due to personalized cancer testing:
1) a significant decrease in mortality and morbidity by using targeting cancer therapies
2) a significant decrease in resistance and side-effects by avoiding chemotherapy
Financial estimates reveal:
1) >Rs.1.3 billion ($8B) in total revenues* by FY05*
2) 5x ROI (Net profit) by FY03*
*Findings based on 25% mid-market penetration at 15% CAGR
Partners:
Scientific solutions providers
Oncologists and Pathologists
Hospitals and commercial labs
Pakistani and overseas VCs and investors
Use of Proceeds:
R&D, labor, materials, marketing, PP&E and working capital
Who we are
Bukhari Genomics is a privately held company committed to the development and commercialization of technologies for accurate and early detection of cancer and genetic disorders.
Through unique expertise, exclusive supplier agreements, and leading-edge biotechnologies, Bukhari Genomicsis developing diagnostic products that are compelling for the healthcare marketplace. The leadership team is composed of successful veterans of diagnostics, medicine, and biotech industries.
We have been successful in reaching our short term goals by securing exclusive supply protection for our technology and by validating the value of our technology in the oncologists' community. We are seeking funding for the establishment of a clinical laboratory. We believe that we can conclude our research and development activities as well as fulfill government regulatory requirements within a relatively short time frame of 4 to 6 months.
We will utilize future profits to properly staff our company to develop equally revolutionary technologies in the niche of genomics, building our company as a world leader in personalized medicine.
End Point
Bukhari Genomics plans to build a lean, profitable business that is ripe for a partnership with top clinical genomics or oncology testing service provider or a biopharmaceutical company in three years.
Growth Strategy
The company's strategy will be to prove the offering is attractive and can gain market share in the biotech industry, healthcare industry, and the medical diagnostic industry. By proving the technology is applicable in multiple industries will likely increase the interest of potential international partners who would come from the research universities, biotech industry or healthcare industry.